Aprindine for treatment of supraventricular tachycardias
| Autor: | Delon Wu, Kenneth M. Rosen, Winston E. Gaum, Fernando Amat-Y-Leon, Douglas P. Zipes, Peter R. Foster, R. Joe Noble |
|---|---|
| Rok vydání: | 1977 |
| Předmět: |
medicine.medical_specialty
Aprindine business.industry Refractory period Atrial fibrillation Accessory pathway medicine.disease Oral administration Internal medicine Anesthesia cardiovascular system Cardiology Medicine In patient cardiovascular diseases Supraventricular tachycardia Cardiology and Cardiovascular Medicine business Atrial flutter medicine.drug |
| Zdroj: | The American Journal of Cardiology. 40:586-596 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/0002-9149(77)90075-3 |
| Popis: | Ten patients with recurrent or continuous Supraventricular tachycardia difficult to control with conventional antiarrhythmic agents were treated with aprindine, a new antiarrhythmic drug. Nine patients had Wolff-Parkinson-White syndrome. An electrophysiologic study was performed before and during oral administration of aprindine. At the time of the first study, circus movement Supraventricular tachycardia was initiated in Patients 1 to 8. During administration of aprindine, circus movement Supraventricular tachycardia could no longer be initiated in Patients 1 to 4 but was initiated with difficulty in Patients 5 and 6 and with greater ease in Patients 7 and 8. In Patient 9, aprindine therapy slowed the ventricular response during atrial flutter from 1:1 conduction over the accessory pathway to 2:1 conduction over the normal pathway; in Patient 10, it slowed the ventricular rate during atrial fibrillation from 140–180 to 80–100 beats/min. Patients 1 to 6, 9 and 10 had an excellent clinical response, but treatment with aprindine was discontinued in Patients 7 and 8. Electrophysiologic evaluation revealed that aprindine produced complete block or increased refractoriness of the accessory pathway in an antegrade direction in all patients and in a retrograde direction in all but two (Patients 7 and 8) tested. Aprindine also slowed conduction in the accessory pathway and, when Supraventricular tachycardia could still be initiated, it occurred at a slower rate. Neurologic side effects occurred primarily during the initial administration and dose adjustment of aprindine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|